GX-188E

BIOLOGICAL5 trials

Sponsors

Genexine, Inc.

Conditions

Cervical CancerCervical Intraepithelial NeoplasiaCervical Intraepithelial Neoplasia 3

Phase 1

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

CompletedNCT03444376

Genexine, Inc.Cervical Cancer

Start: 2018-06-19End: 2023-12-21Updated: 2025-07-30

Phase 2

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

CompletedNCT02139267

Genexine, Inc.Cervical Intraepithelial Neoplasia

Start: 2014-07-31End: 2016-03-31Updated: 2017-07-12

Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

Genexine, Inc.Cervical Intraepithelial Neoplasia

Start: 2015-08-31End: 2018-08-31Updated: 2017-07-12

Unknown Phase

Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation

Genexine, Inc.Cervical Intraepithelial Neoplasia 3

Start: 2014-02-28End: 2018-01-31Updated: 2017-07-12

Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation

Genexine, Inc.Cervical Intraepithelial Neoplasia 3

Start: 2015-03-31End: 2018-11-30Updated: 2017-07-12

Related Papers

GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trial.

2024-07-1310 citations

A phase 1/2a, dose-escalation, safety, and preliminary efficacy study of the RKP00156 vaginal tablet in healthy women and patients with cervical intraepithelial neoplasia 2

Journal of Gynecologic Oncology2024-01-01

Efficacy and safety results of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab administration in patients with HPV 16- and/or 18- positive advanced cervical cancer: Phase II interim analysis results (KEYNOTE-567).

Journal of Clinical Oncology2021-05-2012 citations

Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.

2020-12-01122 citations